June 4, 2024 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC)
Рет қаралды 17,699
Күн бұрынThe Committee will discuss new drug application (NDA) 215455, for midomafetamine (MDMA), submitted by Lykos Therapeutics, for the proposed indication of treatment of post-traumatic stress disorder. The Committee will be asked to discuss the overall benefit-risk profile of the product, including the potential public health impact.
U.S. Food and Drug Administration
Рет қаралды 4,5 М.
U.S. Food and Drug Administration
Рет қаралды 4,9 М.
U.S. Food and Drug Administration
Рет қаралды 182
U.S. Food and Drug Administration
Рет қаралды 66
U.S. Food and Drug Administration
Рет қаралды 9 М.
U.S. Food and Drug Administration
Рет қаралды 12 М.
U.S. Food and Drug Administration
Рет қаралды 470
U.S. Food and Drug Administration
Рет қаралды 2,2 М.
U.S. Food and Drug Administration
Рет қаралды 116
FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-posit...
U.S. Food and Drug Administration
Рет қаралды 1,9 М.
U.S. Food and Drug Administration
Рет қаралды 567
U.S. Food and Drug Administration
Рет қаралды 6 М.